

NCR1 Rabbit pAb

Catalog Number: bs-10027R

Target Protein: NCR1

Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: WB (1:500-2000)

Reactivity: Human, Mouse, Rat (predicted:Pig, Sheep, Cow, Dog, Horse)

Predicted MW: 31 kDa

Entrez Gene: 9437

Swiss Prot: O76036

Source: KLH conjugated synthetic peptide derived from human CD335: 198-206/304.


Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.


Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: The natural cytotoxicity receptors (NCRs) are a recently characterized family of Ig-like activation receptors that appear to be major triggering receptors in tumor cell recognition. NCR1 is a glycoprotein that has two extracellular Ig-like domains followed by a ~40 amino acid residue stalk region, a type I transmembrane domain, and a short cytoplasmic tail. NCR1 has been shown to represent a novel NK cell-specific molecule involved in human NK cell activation. NCR1 has been implicated in NK cell-mediated lysis of several autologous tumor cells and pathogen-infected cell lines.

VALIDATION IMAGES



Sample: Kidney (Mouse) Lysate at 40 ug Spleen (Mouse) Lysate at 40 ug Lymph node (Mouse) Lysate at 40 ug A431(Human) Cell Lysate at 30 ug Raji(Human) Cell Lysate at 30 ug Primary: Anti- NCR1 (bs-10027R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 31 kD Observed band size: 46 kD



Sample: Lane 1: Mouse Spleen tissue lysates Lane 2: Mouse Lung tissue lysates Lane 3: Rat Lymph node tissue lysates Lane 4: Human HL-60 cell lysates Primary: Anti-NCR1 (bs-10027R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 31 kDa Observed band size: 48 kDa

PRODUCT SPECIFIC PUBLICATIONS

[IF=6.43] Pan, Pan, et al. "Black Raspberries Enhance Natural Killer Cell Infiltration into the Colon and Suppress the Progression of Colorectal Cancer." *Frontiers in Immunology* 8 (2017): 997. IHC ; ="Mouse" . 28861089

[IF=1.83] VINDEVOGEL, EVA, et al. "The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer." *Anticancer Research* 36.11 (2016): 5781-5792. IHC ; ="Mouse" . 27793900

[IF=1.26] Jaime-Ramirez et al. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. (2017) *Mol.Ther.Oncolytics*. 5:87-96 IHC ; Mouse . 28812060